Theravance Biopharma Company Profile (NASDAQ:TBPH)

About Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma logoTheravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TBPH
  • CUSIP: N/A
  • Web: www.theravance.com
Capitalization:
  • Market Cap: $1.48892 billion
  • Outstanding Shares: 53,829,000
Average Prices:
  • 50 Day Moving Avg: $34.24
  • 200 Day Moving Avg: $35.37
  • 52 Week Range: $23.15 - $43.44
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.27
  • P/E Growth: -0.04
Sales & Book Value:
  • Annual Revenue: $31.36 million
  • Price / Sales: 47.03
  • Book Value: $4.48 per share
  • Price / Book: 6.12
Profitability:
  • EBIDTA: ($211,250,000.00)
  • Net Margins: -742.59%
  • Return on Equity: -78.74%
  • Return on Assets: -43.79%
Debt:
  • Debt-to-Equity Ratio: 0.93%
  • Current Ratio: 6.74%
  • Quick Ratio: 6.53%
Misc:
  • Average Volume: 276,850 shs.
  • Beta: 2.24
  • Short Ratio: 24.77
 

Frequently Asked Questions for Theravance Biopharma (NASDAQ:TBPH)

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly earnings results on Monday, August, 8th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by $0.01. The company had revenue of $5.47 million for the quarter, compared to the consensus estimate of $6.19 million. Theravance Biopharma had a negative return on equity of 78.74% and a negative net margin of 742.59%. View Theravance Biopharma's Earnings History.

Where is Theravance Biopharma's stock going? Where will Theravance Biopharma's stock price be in 2017?

7 equities research analysts have issued 12-month price objectives for Theravance Biopharma's stock. Their predictions range from $24.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $42.57 in the next year. View Analyst Ratings for Theravance Biopharma.

What are analysts saying about Theravance Biopharma stock?

Here are some recent quotes from research analysts about Theravance Biopharma stock:

  • 1. Needham & Company LLC analysts commented, "Theravance reported top-line results from Phase 2b trial of velusetrag in Gastroparesis. Statistically significant and dose-dependent improvements in gastric emptying were observed across all 3 doses tested. Symptomatic benefits, however, were only observed at lowest dose. Mgmt speculated that excessive gastric emptying into small intestine may have led to a separate set of symptoms negating any benefits. Explanation appears plausible, but we await details at future medical mtg. Regardless, efficacy in 5mg arm is sufficiently strong to justify Phase 3 development, considering both key pre-specified endpoints were met at 4wks (Gastroparesis Cardinal Symptom Index p=0.033 and Gastroparesis Rating Scale p=0.016), w/ all 10 subscales favoring drug over placebo. Effects were observed in both Diabetic and Idiopathic pts and persisted through 12wks. Mgmt plans to meet w/ FDA to discuss Phase 3 design." (8/2/2017)
  • 2. According to Zacks Investment Research, "Theravance’s sole marketed product, Vibativ, continues to perform well, contributing meaningfully to the top line at the company. However, Vibativ witnessed a sequential decline due to seasonality and trends in surgical admissions. Nevertheless, the company’s efforts on the commercialization of Vibativ are encouraging. We are also positive on its efforts to expand the drug’s label, which if approved for additional indications, would be commercially significant. Further, its collaboration agreement with Mylan for revefenacin, a key late-stage pipeline candidate, is a big positive. Theravance’s progress with the rest of the pipeline is also impressive. Shares of the company have significantly outperformed the Medical-Drugs industry in 2016. Moreover, estimates have gone up ahead of the release of the company’s fourth-quarter 2016 results. However, Theravance’s heavy dependence on Vibativ for growth is concerning." (1/3/2017)

Who are some of Theravance Biopharma's key competitors?

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the folowing people:

  • Rick E. Winningham, Chairman of the Board, Chief Executive Officer
  • Renee D. Gala, Senior Vice President, Chief Financial Officer, Treasurer
  • Bradford J. Shafer Esq. J.D., Executive Vice President, General Counsel, Secretary
  • Brett K. Haumann M.D., Senior Vice President - Clinical Development and Chief Medical Officer
  • Sharathchandra S. Hegde, Senior Vice President, Research
  • Frank Pasqualone, Senior Vice President and Chief Commercial Operations Officer
  • Kenneth R. Pitzer, Senior Vice President - Product Strategy and Commercial Planning
  • Shehnaaz Suliman M.D., Senior Vice President - Corporate Development and Strategy
  • Philip D. Worboys Ph.D., Senior Vice President, Translational Science
  • William D. Young, Lead Independent Director

Who owns Theravance Biopharma stock?

Theravance Biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Woodford Investment Management Ltd (20.06%), BlackRock Inc. (6.82%), Vanguard Group Inc. (5.99%), First Manhattan Co. (3.29%), State Street Corp (1.65%) and Northern Trust Corp (0.99%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Henrietta Fore, Plc Glaxosmithkline and Rick E Winningham. View Institutional Ownership Trends for Theravance Biopharma.

Who sold Theravance Biopharma stock? Who is selling Theravance Biopharma stock?

Theravance Biopharma's stock was sold by a variety of institutional investors in the last quarter, including Hillhouse Capital Management Ltd., First Manhattan Co., Balyasny Asset Management LLC, Candriam Luxembourg S.C.A., Old West Investment Management LLC, Goldman Sachs Group Inc., Royce & Associates LP and California State Teachers Retirement System. Company insiders that have sold Theravance Biopharma stock in the last year include Bradford J Shafer and Brett K Haumann. View Insider Buying and Selling for Theravance Biopharma.

Who bought Theravance Biopharma stock? Who is buying Theravance Biopharma stock?

Theravance Biopharma's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Wells Fargo & Company MN, Alps Advisors Inc., State of Wisconsin Investment Board, Northern Trust Corp, TIAA CREF Investment Management LLC and Teachers Advisors LLC. Company insiders that have bought Theravance Biopharma stock in the last two years include Henrietta Fore, Plc Glaxosmithkline and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.

How do I buy Theravance Biopharma stock?

Shares of Theravance Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of Theravance Biopharma stock can currently be purchased for approximately $27.40.


MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  202
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Theravance Biopharma (NASDAQ:TBPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $42.57 (55.37% upside)

Analysts' Ratings History for Theravance Biopharma (NASDAQ:TBPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$45.00MediumView Rating Details
8/16/2017Cantor FitzgeraldSet Price TargetBuy$55.00LowView Rating Details
8/2/2017Needham & Company LLCReiterated RatingBuyHighView Rating Details
5/10/2017Leerink SwannSet Price TargetBuy$47.00LowView Rating Details
3/22/2017Piper Jaffray CompaniesReiterated RatingOverweight$42.00MediumView Rating Details
10/12/2016Robert W. BairdDowngradeNeutral -> Underperform$19.00 -> $24.00N/AView Rating Details
9/19/2016GuggenheimReiterated RatingPositive$40.00N/AView Rating Details
8/3/2016Bank of America CorporationDowngradeNeutral -> UnderperformN/AView Rating Details
(Data available from 8/19/2015 forward)

Earnings

Earnings History for Theravance Biopharma (NASDAQ:TBPH)
Earnings by Quarter for Theravance Biopharma (NASDAQ:TBPH)
Earnings History by Quarter for Theravance Biopharma (NASDAQ TBPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017($1.14)($1.27)$5.07 million$3.09 millionViewListenView Earnings Details
2/27/2017Q416($1.05)($1.36)$5.00 million$5.69 millionViewListenView Earnings Details
8/8/2016Q216($1.05)($1.06)$6.19 million$5.47 millionViewN/AView Earnings Details
5/9/2016Q116($0.96)($1.10)$18.69 million$18.40 millionViewN/AView Earnings Details
3/9/2016Q415($1.62)($1.23)($280,000.00) million$3.90 millionViewN/AView Earnings Details
11/9/2015Q315($1.44)($1.40)$4.24 million$10.70 millionViewN/AView Earnings Details
8/10/2015Q215($1.51)($1.42)$4.25 million$7.10 millionViewListenView Earnings Details
3/10/2015Q414($1.70)($2.02)$2.01 million$1.30 millionViewN/AView Earnings Details
11/6/2014Q3 14($1.85)($1.72)$1.08 million$6.34 millionViewN/AView Earnings Details
8/13/2014($0.56)($1.83)$1.01 million$2.97 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Theravance Biopharma (NASDAQ:TBPH)
2017 EPS Consensus Estimate: ($4.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.04)($1.04)($1.04)
Q2 20171($1.07)($1.07)($1.07)
Q3 20171($1.26)($1.26)($1.26)
Q4 20171($1.31)($1.31)($1.31)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Theravance Biopharma (NASDAQ:TBPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Theravance Biopharma (NASDAQ:TBPH)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 82.77%
Insider Trades by Quarter for Theravance Biopharma (NASDAQ:TBPH)
Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)
Insider Trades by Quarter for Theravance Biopharma (NASDAQ:TBPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017Henrietta ForeDirectorBuy6,000$23.99$143,940.00View SEC Filing  
8/11/2017Rick E WinninghamCEOBuy10,000$24.50$245,000.00View SEC Filing  
3/7/2017Brett K HaumannSVPSell424$30.80$13,059.20View SEC Filing  
3/6/2017Brett K HaumannSVPSell13,576$31.52$427,915.52View SEC Filing  
8/25/2016Brett K HaumannSVPSell4,491$27.99$125,703.09View SEC Filing  
8/22/2016Bradford J ShaferEVPSell49,122$27.46$1,348,890.12View SEC Filing  
8/19/2016Brett K HaumannSVPSell9,509$27.97$265,966.73View SEC Filing  
3/14/2016Plc GlaxosmithklineMajor ShareholderBuy1,301,015$23,028,000.00$29,959,773,420,000.00View SEC Filing  
10/7/2015Plc GlaxosmithklineMajor ShareholderBuy44,574$607,544.00$27,080,666,256.00View SEC Filing  
8/18/2015Burton G MalkielDirectorBuy10,000$12.92$129,200.00View SEC Filing  
8/18/2015Junning LeeVPBuy9,000$12.90$116,100.00View SEC Filing  
8/17/2015Renee D GalaCFOBuy10,000$12.18$121,800.00View SEC Filing  
8/17/2015Rick E WinninghamCEOBuy80,000$11.86$948,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Theravance Biopharma (NASDAQ:TBPH)
Latest Headlines for Theravance Biopharma (NASDAQ:TBPH)
Source:
DateHeadline
americanbankingnews.com logoTheravance Biopharma, Inc. (TBPH) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 18 at 4:42 AM
americanbankingnews.com logoCantor Fitzgerald Analysts Give Theravance Biopharma Inc (TBPH) a $55.00 Price Target
www.americanbankingnews.com - August 16 at 8:58 PM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - August 16 at 5:40 PM
americanbankingnews.com logoZacks: Analysts Expect Theravance Biopharma, Inc. (NASDAQ:TBPH) Will Announce Quarterly Sales of $3.59 Million
www.americanbankingnews.com - August 12 at 1:34 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Theravance Biopharma Inc.
finance.yahoo.com - August 12 at 8:20 AM
americanbankingnews.com logoTheravance Biopharma, Inc. (NASDAQ:TBPH) CEO Rick E. Winningham Purchases 10,000 Shares
www.americanbankingnews.com - August 11 at 8:16 PM
americanbankingnews.com logoTheravance Biopharma, Inc. (NASDAQ:TBPH) Director Buys $143,940.00 in Stock
www.americanbankingnews.com - August 11 at 8:16 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Theravance Biopharma, Inc. Decreased by Analyst (NASDAQ:TBPH)
www.americanbankingnews.com - August 11 at 8:12 AM
americanbankingnews.com logoTheravance Biopharma, Inc. (TBPH) Expected to Post Earnings of -$1.14 Per Share
www.americanbankingnews.com - August 10 at 9:52 AM
streetinsider.com logoTheravance Biopharma (TBPH) Reports Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis
www.streetinsider.com - August 9 at 8:01 AM
finance.yahoo.com logoTheravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis
finance.yahoo.com - August 9 at 8:01 AM
finance.yahoo.com logoTheravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 9 at 8:01 AM
finance.yahoo.com logoEdited Transcript of TBPH earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 8:01 AM
seekingalpha.com logoTheravance Biopharma (TBPH) Updates On Results From Phase 2b Study Of Velusetrag - Slideshow
seekingalpha.com - August 5 at 7:36 AM
americanbankingnews.com logoFY2020 EPS Estimates for Theravance Biopharma, Inc. Boosted by Leerink Swann (NASDAQ:TBPH)
www.americanbankingnews.com - August 4 at 7:58 PM
finance.yahoo.com logoCorporate News Blog - Theravance Biopharma’s Velusetrag Successful in Mid-Stage Gastroparesis Study
finance.yahoo.com - August 4 at 8:54 AM
americanbankingnews.com logoTheravance Biopharma, Inc. (TBPH) Downgraded by BidaskClub
www.americanbankingnews.com - August 2 at 7:36 PM
americanbankingnews.com logoTheravance Biopharma's (NASDAQ:TBPH) "Buy" Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - August 2 at 4:38 PM
finance.yahoo.com logoTheravance Biopharma to Report Second Quarter 2017 Financial Results and Business Update on August 8, 2017
finance.yahoo.com - August 2 at 7:39 AM
finance.yahoo.com logoTheravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis
finance.yahoo.com - August 2 at 7:39 AM
americanbankingnews.com logoTheravance Biopharma, Inc. (NASDAQ:TBPH) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - August 1 at 11:04 PM
finance.yahoo.com logoTheravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Development and Strategy
finance.yahoo.com - August 1 at 6:48 AM
finance.yahoo.com logoTheravance Biopharma, Inc. – Value Analysis (NASDAQ:TBPH) : July 31, 2017
finance.yahoo.com - August 1 at 6:48 AM
americanbankingnews.com logoTheravance Biopharma, Inc. (NASDAQ:TBPH) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:26 AM
nasdaq.com logoOversold Conditions For Theravance Biopharma
www.nasdaq.com - July 29 at 7:45 AM
nasdaq.com logoNotable Two Hundred Day Moving Average Cross - TBPH
www.nasdaq.com - July 28 at 8:33 AM
americanbankingnews.com logoTheravance Biopharma, Inc. (TBPH) Cut to Sell at BidaskClub
www.americanbankingnews.com - July 27 at 8:30 PM
finance.yahoo.com logoETFs with exposure to Theravance Biopharma, Inc. : July 25, 2017
finance.yahoo.com - July 26 at 8:36 AM
americanbankingnews.com logoTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 24 at 10:54 AM
americanbankingnews.com logoTheravance Biopharma Inc (NASDAQ:TBPH) PT Set at $55.00 by Cantor Fitzgerald
www.americanbankingnews.com - July 23 at 4:20 PM
americanbankingnews.com logo Brokerages Anticipate Theravance Biopharma, Inc. (TBPH) Will Announce Quarterly Sales of $4.06 Million
www.americanbankingnews.com - July 22 at 7:32 AM
americanbankingnews.com logoZacks: Analysts Anticipate Theravance Biopharma, Inc. (NASDAQ:TBPH) Will Post Earnings of -$1.13 Per Share
www.americanbankingnews.com - July 20 at 10:15 PM
finance.yahoo.com logoTheravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : July 17, 2017
finance.yahoo.com - July 18 at 8:49 AM
finance.yahoo.com logoETFs with exposure to Theravance Biopharma, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 9:17 AM
americanbankingnews.com logoTheravance Biopharma, Inc. to Post FY2017 Earnings of ($4.46) Per Share, Cantor Fitzgerald Forecasts (TBPH)
www.americanbankingnews.com - July 6 at 8:45 AM
americanbankingnews.com logoZacks: Analysts Anticipate Theravance Biopharma, Inc. (TBPH) Will Post Quarterly Sales of $4.06 Million
www.americanbankingnews.com - June 28 at 10:33 AM
americanbankingnews.com logoTheravance Biopharma, Inc. (TBPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 27 at 9:26 AM
americanbankingnews.com logoZacks: Analysts Anticipate Theravance Biopharma, Inc. (TBPH) to Post -$1.13 EPS
www.americanbankingnews.com - June 26 at 8:40 PM
americanbankingnews.com logoTheravance Biopharma, Inc. (TBPH) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - June 24 at 3:38 PM
americanbankingnews.com logoCantor Fitzgerald Initiates Coverage on Theravance Biopharma, Inc. (TBPH)
www.americanbankingnews.com - June 16 at 10:06 AM
finance.yahoo.com logoTheravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : June 15, 2017
finance.yahoo.com - June 15 at 4:37 PM
finance.yahoo.com logoTheravance (TBPH) Down 5.8% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 13 at 9:36 AM
prnewswire.com logoNew Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin ...
www.prnewswire.com - June 7 at 10:00 AM
finance.yahoo.com logoETFs with exposure to Theravance Biopharma, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 6:42 PM
finance.yahoo.com logoNew Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin) Against Difficult-to-Treat MRSA and MSSA Pathogens Reported at ASM Microbe 2017
finance.yahoo.com - June 5 at 1:41 PM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - June 3 at 12:57 AM
finance.yahoo.com logoTheravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 3:17 PM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) Expected to Post Quarterly Sales of $4.06 Million
www.americanbankingnews.com - June 2 at 1:12 PM
americanbankingnews.com logoZacks: Analysts Expect Theravance Biopharma Inc (TBPH) Will Post Earnings of -$1.16 Per Share
www.americanbankingnews.com - May 31 at 4:44 PM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 31 at 10:02 AM

Social

Chart

Theravance Biopharma (TBPH) Chart for Saturday, August, 19, 2017

This page was last updated on 8/19/2017 by MarketBeat.com Staff